Medical Uses
Crenessity (crinecerfont) is a corticotropin-releasing factor type 1 receptor antagonist used as adjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients aged 4 years and older with classic congenital adrenal hyperplasia (CAH).
Recommended Dosage: The recommended dosage of Crinecerfont for adult patients is 100 mg orally, twice daily with a meal in the morning and evening. Take capsules orally and swallow whole with liquid.
The recommended dosage of Crinecerfont for pediatric patients aged 4 years and older is weight-based and administered orally, twice daily with a meal in the morning and evening.
- pediatric patients 10 kg to less than 20 kg: The recommended dose is 25 mg orally twice daily
- pediatric patients 20 kg to less than 55 kg: The recommended dose is 50 mg orally twice daily
- pediatric patients greater than or equal to 55 kg: The recommended dose is 100 mg orally twice daily
If a dose or doses are missed, advise the patient to take one dose as soon as possible (even if it is soon before the next scheduled dose) and then resume the regular dosing schedule.